ATE525083T1 - Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung - Google Patents
Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindungInfo
- Publication number
- ATE525083T1 ATE525083T1 AT04797450T AT04797450T ATE525083T1 AT E525083 T1 ATE525083 T1 AT E525083T1 AT 04797450 T AT04797450 T AT 04797450T AT 04797450 T AT04797450 T AT 04797450T AT E525083 T1 ATE525083 T1 AT E525083T1
- Authority
- AT
- Austria
- Prior art keywords
- pharmaceutical composition
- asp
- insulin
- analog
- active compound
- Prior art date
Links
- 108090001061 Insulin Proteins 0.000 title abstract 2
- 230000002473 insulinotropic effect Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title 1
- 102000004877 Insulin Human genes 0.000 title 1
- 229940125396 insulin Drugs 0.000 title 1
- 239000004094 surface-active agent Substances 0.000 title 1
- 235000012054 meals Nutrition 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200301689 | 2003-11-13 | ||
| PCT/DK2004/000788 WO2005046716A1 (en) | 2003-11-13 | 2004-11-12 | Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and a insulin peptide of short time action for treatment of diabetes and bulimia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE525083T1 true ATE525083T1 (de) | 2011-10-15 |
Family
ID=34585770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04797450T ATE525083T1 (de) | 2003-11-13 | 2004-11-12 | Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1684793B1 (de) |
| JP (1) | JP4800959B2 (de) |
| AT (1) | ATE525083T1 (de) |
| ES (1) | ES2373660T3 (de) |
| WO (1) | WO2005046716A1 (de) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5562510B2 (ja) | 2001-06-28 | 2014-07-30 | ノヴォ ノルディスク アー／エス | 修飾ｇｌｐ−１の安定な処方剤 |
| CA2820537C (en) | 2003-04-23 | 2015-10-20 | Valeritas, Inc. | Hydraulically actuated pump for fluid administration |
| CN102940879B (zh) | 2003-06-03 | 2017-06-06 | 诺沃挪第克公司 | 稳定化的药物肽组合物 |
| EP1633391B1 (de) | 2003-06-03 | 2011-10-19 | Novo Nordisk A/S | Stabilisierte pharmazeutische peptid zusammensetzungen |
| PL3300721T5 (pl) * | 2003-11-20 | 2025-11-17 | Novo Nordisk A/S | Preparaty peptydowe zawierające glikol propylenowy, które są optymalne do produkcji i do zastosowania w urządzeniu do wstrzykiwania |
| EP1694356B1 (de) | 2003-12-09 | 2011-02-16 | Novo Nordisk A/S | Regulierung der nahrungspräferenz mit glp-1-agonisten |
| WO2006014425A1 (en) | 2004-07-02 | 2006-02-09 | Biovalve Technologies, Inc. | Methods and devices for delivering glp-1 and uses thereof |
| EP1789434B1 (de) | 2004-08-31 | 2013-11-20 | Novo Nordisk A/S | Verwendung von tris(hydroxymethyl)-aminomethan zur stabilisierung von peptiden, polypeptiden und proteinen |
| EP1814581B1 (de) * | 2004-11-12 | 2016-03-16 | Novo Nordisk A/S | Stabile peptidformulierungen enthaltend ein acyliertes glp-1 analogon und ein basales insulin |
| ES2735533T3 (es) * | 2004-11-12 | 2019-12-19 | Novo Nordisk As | Formulaciones estables de GLP-1 |
| RU2438719C2 (ru) | 2006-03-30 | 2012-01-10 | ВАЛЕРИТАС Инк. | Многокартриджное устройство для введения жидкости |
| US20090318353A1 (en) * | 2006-08-25 | 2009-12-24 | Novo Nordisk A/S | Acylated Exendin-4 Compounds |
| DK2597103T3 (en) | 2007-11-16 | 2017-02-13 | Novo Nordisk As | Stable pharmaceutical compositions comprising liraglutide and degludec |
| CN102026666B (zh) * | 2007-12-11 | 2013-10-16 | 常山凯捷健生物药物研发（河北）有限公司 | 促胰岛素肽缀合物制剂 |
| NZ586590A (en) | 2008-01-09 | 2012-06-29 | Sanofi Aventis Deutschland | Insulin analogues or derivatives having an extremely delayed time-action profile |
| LT2349324T (lt) * | 2008-10-17 | 2017-12-27 | Sanofi-Aventis Deutschland Gmbh | Insulino ir glp-1 agonisto derinys |
| JP5832439B2 (ja) | 2009-11-13 | 2015-12-16 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物 |
| CN102711804B (zh) | 2009-11-13 | 2015-09-16 | 赛诺菲-安万特德国有限公司 | 包含glp-1激动剂和甲硫氨酸的药物组合物 |
| WO2011086093A2 (en) * | 2010-01-12 | 2011-07-21 | Novo Nordisk A/S | Pharmaceutical compositions for oral administration of insulin peptides |
| CN103179978A (zh) | 2010-08-30 | 2013-06-26 | 赛诺菲-安万特德国有限公司 | Ave0010用于制造供治疗2型糖尿病用的药物的用途 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| WO2013030160A1 (en) | 2011-08-29 | 2013-03-07 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| AR092862A1 (es) * | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| SG10201705097PA (en) | 2012-12-21 | 2017-07-28 | Sanofi Sa | Functionalized exendin-4 derivatives |
| TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物 |
| EP3080154B1 (de) | 2013-12-13 | 2018-02-07 | Sanofi | Duale glp-1/gip-rezeptoragonisten |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| JP6735674B2 (ja) | 2014-01-09 | 2020-08-05 | サノフイＳａｎｏｆｉ | インスリンアスパルトの安定化された医薬製剤 |
| EP3091995B1 (de) | 2014-01-09 | 2024-03-20 | Sanofi | Stabilisierte pharmazeutische formulierungen von insulin aspart |
| US9895424B2 (en) | 2014-01-09 | 2018-02-20 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| MA41138B1 (fr) | 2014-12-12 | 2023-07-31 | Sanofi Aventis Deutschland | Formulation à rapport fixe d'insuline glargine/lixisenatide |
| AR102869A1 (es) * | 2014-12-16 | 2017-03-29 | Lilly Co Eli | Composiciones de insulina de rápida acción |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| GB201607918D0 (en) | 2016-05-06 | 2016-06-22 | Arecor Ltd | Novel formulations |
| HRP20240485T1 (hr) | 2017-08-24 | 2024-07-05 | Novo Nordisk A/S | Pripravci glp-1 i njihova upotreba |
| MX2022009844A (es) | 2020-02-18 | 2022-09-05 | Novo Nordisk As | Composiciones y usos del peptido similar al glucagon-1 (glp-1). |
| KR20230121823A (ko) * | 2020-12-16 | 2023-08-21 | 질랜드 파마 에이/에스 | Glp-1/glp-2 이중 효능제의 약학적 조성물 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH25772A (en) * | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| NZ232375A (en) * | 1989-02-09 | 1992-04-28 | Lilly Co Eli | Insulin analogues modified at b29 |
| US5514646A (en) * | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
| US6458924B2 (en) * | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| ES2283025T3 (es) * | 1996-08-30 | 2007-10-16 | Novo Nordisk A/S | Derivados de glp-1.1. |
| AU4112497A (en) * | 1996-08-30 | 1998-03-19 | Novo Nordisk A/S | Glp-2 derivatives |
| DE69831673C5 (de) * | 1997-01-07 | 2015-01-22 | Amylin Pharmaceuticals, Llc | Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme |
| JP2003503356A (ja) * | 1999-06-25 | 2003-01-28 | メドトロニック ミニメド インコーポレイテッド | 多剤糖尿病治療 |
| EP1076066A1 (de) * | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptide zur Senkung des Blutglukosespiegels |
| AU2353701A (en) * | 2000-01-11 | 2001-07-24 | Novo Nordisk A/S | Transepithelial delivery of glp-1 derivatives |
| EP1432430A4 (de) * | 2001-08-28 | 2006-05-10 | Lilly Co Eli | Vormischungen von glp-1 und basalinsulin |
-
2004
- 2004-11-12 WO PCT/DK2004/000788 patent/WO2005046716A1/en not_active Ceased
- 2004-11-12 ES ES04797450T patent/ES2373660T3/es not_active Expired - Lifetime
- 2004-11-12 AT AT04797450T patent/ATE525083T1/de not_active IP Right Cessation
- 2004-11-12 JP JP2006538658A patent/JP4800959B2/ja not_active Expired - Fee Related
- 2004-11-12 EP EP04797450A patent/EP1684793B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP4800959B2 (ja) | 2011-10-26 |
| JP2007510675A (ja) | 2007-04-26 |
| EP1684793A1 (de) | 2006-08-02 |
| WO2005046716A1 (en) | 2005-05-26 |
| EP1684793B1 (de) | 2011-09-21 |
| ES2373660T3 (es) | 2012-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE525083T1 (de) | Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung | |
| WO2006051103A3 (en) | Stable formulations of peptides | |
| MXPA05007470A (es) | Metodo para reducir la morbilidad y mortalidad cardiovascular en pacientes prediabeticos y pacientes con diabetes de tipo 2. | |
| DK1143989T3 (da) | Exendiner til glucagonundertrykkelse | |
| WO2009063072A3 (en) | Pharmaceutical compositions comprising glp-1 peptides or exendin-4 and a basal insulin peptide | |
| AU2003243750A1 (en) | Rapidly dissolving micro-perforator for drug delivery and other applications | |
| NO20063436L (no) | Intranasal administrasjon av glukose-regulerende peptider | |
| WO2006051110A3 (en) | Stable formulations of insulinoptropic peptides | |
| EP2186824A3 (de) | Chronisches Behandlungsschema mit Glucagon-ähnlichen insulinotropischen Peptiden | |
| AU2003234529A1 (en) | Glp-1 gene delivery for the treatment of type 2 diabetes | |
| CL2009001899A1 (es) | Composicion farmaceutica que comprende: i) un antagonista del receptor de at1 o una sal, ii) un sensibilizante a la insulina o una sal y iii) un vehiculo farmaceuticamente aceptable; uso para la prevencion, demora de progreso o tratamiento de hipertension, diabetes, entre otras (div. sol. 2034-01). | |
| AU2003295614A8 (en) | Delivery of pharmaceutical agents via the human insulin receptor | |
| TNSN03116A1 (en) | Pulmonary administration of chemically modified insulin | |
| DK1180121T3 (da) | Langtidsvirkende insulinotrope peptider | |
| ATE541582T1 (de) | Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen | |
| WO2006097535A3 (en) | Peptide agonists of the glucagon family with secretin like activity | |
| AU2003279253A1 (en) | Silicone blends and composites for drug delivery | |
| ATE354362T1 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff | |
| MX2023014771A (es) | Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso. | |
| ZA200208761B (en) | Pharmaceutical form of administration for peptides, methods for its production and use. | |
| EA200702116A1 (ru) | Фармацевтическая дозированная форма (варианты) с контролируемым высвобождением антигипергликемического средства в комбинации с производным тиазолидиндиона | |
| Youn et al. | Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation | |
| CA3251240A1 (en) | DUAL GLP-1 AND GLUCAGON AGONIST PEPTIDES WITH IMPROVED BIOLOGICAL STABILITY | |
| PL1609481T3 (pl) | Nadająca się do wstrzykiwania kompozycja farmaceutyczna zawierająca diklofenak sodowy, beta-cyklodekstrynę i polisorbat | |
| EP1110568A3 (de) | Medikamenteninfusionsspritze |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |